A source of hope for platinum-resistant ovarian cancer
· Among the 94 patients with high-grade serous ovarian cancer who received treatment in this study 11 (12 ) had primary platinum-refractory disease an understudied subpopulation with a substantially worse prognosis. For this reason as was the case in the AURELIA trial refractory patients are often excluded from clinical studies.
Get Price
Management of Platinum ResistantRefractory Ovarian
· Ovarian cancer accounts for 3 of cancer deaths among women and is the most lethal gynecological malignancy. The five year survival for all stages collectively is 45.6 and relapsed ovarian cancer is incurable. Platinum resistance is a major prognostic determinant but the molecular pathways involved in resistance mechanism are unknown.
Get Price
Phase 1b‐2a study to reverse platinum resistance through
· Platinum-resistant or platinum-refractory epithelial ovarian cancer was chosen as a model for the following 4 reasons advanced epithelial ovarian cancer displays multiple hypermethylation phenotypes involving known tumor suppressor genes carboplatin has significant efficacy in treating ovarian cancer although single-agent carboplatin induces
Get Price
Prolonged stabilization of platinum-refractory ovarian
· The prognosis of platinum-refractory ovarian cancer is generally unfavorable with a low response to additional chemotherapy. 8 Whether continued treatment of patients with advanced ovarian cancer who do not respond to conventional chemotherapy confers any
Get Price
Treatment of platinum refractory or resistant ovarian cancer
· In The Lancet Oncology Radoslav Chekerov and colleagues1 report the results of a randomised phase 2 trial of the efficacy and safety of adding sorafenib (an oral tyrosine kinase inhibitor of the VEGF receptor and Ras Raf MEK and ERK signalling pathways) to topotecan during chemotherapy and in maintenance in recurrent platinum-resistant or platinum-refractory ovarian cancer.1 The
Get Price
Biomarkers of platinum resistance in ovarian cancer what
· The Gynecologic Cancer InterGroup (GCOG) consensus statement recommended the following timelines for platinum response classifications (1) Platinum-refractory progression while receiving last line of platinum-based therapy or within 4 weeks of last platinum dose (2) Platinum-resistant progression-free interval since last line of platinum of
Get Price
Avelumab in platinum-resistant/refractory ovarian cancer
· Methods. Women with PRROC ≤3 prior lines for platinum-sensitive disease and no prior therapy for platinum-resistant disease were randomized 1 1 1 to Ave (10 mg/kg Q2W) Ave PLD (40 mg/m 2 Q4W) or PLD. Pts were stratified by platinum status (refractory vs resistant) prior regimens (1 vs 2 or 3) and bulky disease (tumor ≥5 vs < 5 cm).
Get Price
Target Therapy in Platinum-Refractory/Resistant Ovarian
Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer From Preclinical Findings to Current Clinical Practice () Nicoletta Staropoli Cirino Botta Domenico Ciliberto Lucia Fiorillo Antonina Maria De Angelis Caterina Viscomi Simona Gualtieri Angela Salvino Pierfrancesco Tassone Pierosandro Tagliaferri Medical
Get Price
Prolonged stabilization of platinum-refractory ovarian
· The prognosis of platinum-refractory ovarian cancer is generally unfavorable with a low response to additional chemotherapy. Whether continued treatment of patients with advanced ovarian cancer who do not respond to conventional chemotherapy confers any
Get Price
A brief review of the management of platinum-resistant
· Refractory Relapse during or within 4 weeks following platinum-based chemotherapy. Resistant Relapse under 6 months from last platinum therapy as platinum resistant. Partially platinum sensitive Relapse between 6 and 12 months. Platinum sensitive Relapse after more than 12 months. Platinum-resistant and platinum-refractory disease which is uniformly fatal carries the worst
Get Price
Understanding Recurrent or Progressive Ovarian Cancer
Platinum refractory cancer continues to grow while on treatment or recurs within a month after the last platinum treatment. Non-platinum drugs are prescribed to treat it. In addition to standard chemotherapy there are new drugs in various stages of clinical development that may also be effective. Some of these have clinical results available.
Get Price
Phase 1b‐2a study to reverse platinum resistance through
· Platinum-resistant or platinum-refractory epithelial ovarian cancer was chosen as a model for the following 4 reasons advanced epithelial ovarian cancer displays multiple hypermethylation phenotypes involving known tumor suppressor genes carboplatin has significant efficacy in treating ovarian cancer although single-agent carboplatin induces
Get Price
Platinum-Resistant and Refractory Ovarian Cancer
· Ovarian cancer patients with platinum-resistant and -refractory disease have the lowest response rates to salvage chemotherapy. Various chemotherapeutic agents such as paclitaxel liposomal doxorubicin topotecan docetaxel platinum etoposide ifosfamide gemcitabine and vinorelbine are available and result in response rates of 7–40 .
Get Price
platinum refractory Cancer Survivors Network
· it says in some definitions "Platinum-refractory disease was defined as cancer with documented tumor progression during platinum-based treatment or recurrence within 6 months after platinum-based chemoradiotherapy"
Get PricePembrolizumab for platinum refractory small cell carcinoma
78-year-old man with metastatic platinum refractory small cell carcinoma of the prostate who was treated with pembrolizumab with good partial response. This case supports that checkpoint inhibitors could be of a benefit for such rare cancers and more investigation is warranted. and was found to have significant prostate cancer involving the
Get Price
NICE s rejection of pembrolizumab for platinum-refractory
· However in the final appraisal review in March 2020 NICE recommended against the use of pembrolizumab for patients with platinum-refractory mUC withdrawing it from the Cancer Drugs Fund for
Get Price
Understanding Recurrent or Progressive Ovarian Cancer
Platinum refractory cancer continues to grow while on treatment or recurs within a month after the last platinum treatment. Non-platinum drugs are prescribed to treat it. In addition to standard chemotherapy there are new drugs in various stages of clinical development that may also be effective. Some of these have clinical results available.
Get Price
What are the treatment recommendations for platinum
· Markman M Webster K Zanotti K Kulp B Peterson G Belinson J. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol. 2003 Sep. 90(3) 593-6.
Get Price
Understanding Recurrent or Progressive Ovarian Cancer
Platinum refractory cancer continues to grow while on treatment or recurs within a month after the last platinum treatment. Non-platinum drugs are prescribed to treat it. In addition to standard chemotherapy there are new drugs in various stages of clinical development that may also be effective. Some of these have clinical results available.
Get Price
Treatment Patterns and Health Outcomes in Platinum
Objective The objective of this article is to describe real-world treatment patterns and outcomes in patients with platinum-refractory/resistant epithelial ovarian fallopian tube or primary peritoneal cancer (PRROC) in the United States United Kingdom and Canada. Methods/Materials Physicians retrospectively reviewed medical records of women aged 18 years or older who were diagnosed with
Get Price
Prolonged stabilization of platinum-refractory ovarian
· The prognosis of platinum-refractory ovarian cancer is generally unfavorable with a low response to additional chemotherapy. Whether continued treatment of patients with advanced ovarian cancer who do not respond to conventional chemotherapy confers any
Get Price
Treatment Patterns and Health Outcomes in Platinum
Objective The objective of this article is to describe real-world treatment patterns and outcomes in patients with platinum-refractory/resistant epithelial ovarian fallopian tube or primary peritoneal cancer (PRROC) in the United States United Kingdom and Canada. Methods/Materials Physicians retrospectively reviewed medical records of women aged 18 years or older who were diagnosed with
Get PricePlatinum RefractoryOvarian Cancer CommunityInspire
· There s a difference on how platinum efficacy is defined depending on the indication. Many clinical trials say you re refractory if your cancer progresses within 3 months after your last platinum. On the opposite end of the spectrum my oncologist calls me platinum sensitive because I had great responses every time I had it regardless of the
Get PriceA Recurrent Platinum Refractory Ovarian Cancer Patient
· A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet. Hope Cottrill MD Stephanie Cason Scott Caroen Bryan Oronsky MD and Elvis Donaldson MD. Journal of Investigative Medicine High Impact Case Reports 2018 10.1177/ Share. Share.
Get Price
Pembrolizumab for platinum refractory small cell carcinoma
78-year-old man with metastatic platinum refractory small cell carcinoma of the prostate who was treated with pembrolizumab with good partial response. This case supports that checkpoint inhibitors could be of a benefit for such rare cancers and more investigation is warranted. and was found to have significant prostate cancer involving the
Get Price
Targeted therapy and immunotherapy for platinum-refractory
· Platinum-refractory ovarian cancer patients have shorter progression-free survival and overall survival (OS) than progressive platinum-resistant patients with ovarian cancer. 7 Ovarian endometriosis can lead to squamous differentiation in endometrioid adenocarcinomas 8 which are classified as adenosquamous carcinomas if they are malignant.
Get Price
Understanding Recurrent or Progressive Ovarian Cancer
Platinum refractory cancer continues to grow while on treatment or recurs within a month after the last platinum treatment. Non-platinum drugs are prescribed to treat it. In addition to standard chemotherapy there are new drugs in various stages of clinical development that may also be effective. Some of these have clinical results available.
Get Price
Immunotherapy for platinum-resistant ovarian cancer
· The Gynecologic Cancer InterGroup (GCOG) consensus statement recommended the following timelines for platinum response classifications (1) Platinum-refractory progression while receiving last line of platinum-based therapy or within 4 weeks of last platinum dose (2) Platinum-resistant progression-free interval since last line of platinum of
Get PricePlatinum RefractoryOvarian Cancer CommunityInspire
· There s a difference on how platinum efficacy is defined depending on the indication. Many clinical trials say you re refractory if your cancer progresses within 3 months after your last platinum. On the opposite end of the spectrum my oncologist calls me platinum sensitive because I had great responses every time I had it regardless of the
Get Price
